Cost Guide · GLP-1 Medications
How Much Does Ozempic Cost in 2026? (With and Without Insurance)
Updated
2026 Pricing
Pricing reviewed September 2026
| Scenario | Monthly | Notes |
|---|---|---|
| No insurance — NovoCare Pharmacy intro | $199 | First two fills of 0.25 mg or 0.5 mg, direct from Novo Nordisk (offer runs through Dec 31, 2026).[4] |
| No insurance — NovoCare Pharmacy standard | $349 – $499 | $349 for 0.25/0.5/1 mg; $499 for 2 mg. U.S. prescription required.[4] |
| Commercial insurance — typical copay | Varies by plan | Type 2 diabetes indication, prior authorization approved. |
| Commercial insurance + NovoCare Savings Card | As low as $25 | For up to a 3-month supply; maximum savings $100/month; government beneficiaries excluded.[4][5] |
| Medicare Part D (diabetes only) | Varies by plan | In 2026, Medicare Part D out-of-pocket spending is capped at $2,100.[6] Not covered for weight loss. |
| Physician-supervised program (medication + care) | $400 – $900 above medication cost | Editorial estimate: typical range reported by practices; not a national average. |
| Ozempic pill (oral semaglutide, formerly Rybelsus) | From $149 | NovoCare self-pay pricing starts at $149/month.[4] |
GLP-1 pricing, manufacturer programs, and insurance coverage shift frequently. Haute MD re-verifies this page against Novo Nordisk, NovoCare, and CMS sources at least quarterly. Confirm current pricing with your pharmacy or prescriber before making a treatment decision.
Pricing Detail
What Determines the Price
Ozempic is manufactured by Novo Nordisk and remains under patent in the United States. Novo Nordisk plans to lower Ozempic's list price to $675/month on Jan 1, 2027.[3]
What a patient actually pays is set by four levers: (1) insurance status and the specific formulary tier; (2) the diagnosis on the prescription (type 2 diabetes is covered far more broadly than off-label weight loss); (3) whether the NovoCare Savings Card or NovoCare Pharmacy self-pay program applies; and (4) pharmacy choice, since cash prices vary materially between chains. U.S. prices for the same medication run 5–10× higher than in most European countries because U.S. pricing is set without centralized negotiation.
Coverage
Insurance Coverage Requirements
Commercial insurance: most plans cover Ozempic for type 2 diabetes when prior authorization criteria are met — typically a documented diabetes diagnosis, an HbA1c above a plan-defined threshold, and prior trial or contraindication to first-line oral agents (metformin most often). Copays vary by plan and formulary tier.
Medicare Part D: covers Ozempic for type 2 diabetes only. In 2026, Medicare Part D out-of-pocket spending is capped at $2,100,[6] which can substantially reduce annual cost for high-utilizers. Medicare does not cover Ozempic when prescribed solely for weight loss.
Medicaid: coverage varies state by state for diabetes; weight-loss coverage is rare. Confirm with your specific state Medicaid program.
Off-label weight loss: most commercial plans deny Ozempic when the diagnosis is obesity rather than diabetes. Patients seeking GLP-1 therapy for weight management generally need to either switch to a weight-loss-indicated agent (Wegovy or Zepbound) or pay cash.
Manufacturer Programs
Manufacturer Savings Programs
NovoCare Savings Card: for commercially insured patients with a type 2 diabetes prescription, this card can reduce out-of-pocket cost to as little as $25 for up to a 3-month supply (maximum savings $100/month; government beneficiaries excluded).[4][5]
NovoCare Pharmacy self-pay: Novo Nordisk's direct-to-patient pharmacy ships Ozempic to U.S. addresses with a valid prescription. The first two fills of the 0.25 mg or 0.5 mg dose are offered at an introductory $199 per month (offer runs through Dec 31, 2026).[4] After the introductory fills, pricing is $349/month for the 0.25, 0.5, and 1 mg pens and $499/month for the 2 mg pen.
Ozempic pill (oral semaglutide): NovoCare now sells an Ozempic pill, with self-pay pricing that starts at $149/month.[4] Strict empty-stomach dosing rules apply.
What to Avoid
Why Compounded Semaglutide Is Cheaper — and Riskier
Compounded semaglutide marketed by online clinics and med-spas is often cheaper than brand-name Ozempic — and the least medical. These products are not FDA-approved.[8]
The FDA has documented dosing errors, adverse events, and the use of semaglutide salt forms (semaglutide sodium, semaglutide acetate) that are not the same active ingredient as Ozempic. With semaglutide off the FDA shortage list, the legal basis for routine compounding has narrowed sharply.
What you save in dollars, you risk in product quality, dose accuracy, and the absence of physician supervision. A board-certified physician overseeing FDA-approved Ozempic — at NovoCare cash-pay tiers if needed — is the safer path.
Physician-Supervised Care
What a Physician-Supervised Program Includes — and What That Costs
The medication is only part of the bill. A real Ozempic program — the kind Haute MD physicians build — also pays for the medicine around it: baseline labs, body composition, nutrition therapy, training programming, and quarterly reassessment.
The figures below are editorial estimates: typical ranges reported by practices, not a national average.
- ·New-patient consult and intake: typically $300–$750 cash, often covered as an office visit by commercial insurance.
- ·Baseline lab panel (CBC, CMP, HbA1c, lipid panel, TSH, vitamin D, hormone panel where indicated): $150–$600 cash, often covered by insurance with appropriate diagnosis codes.
- ·Body-composition assessment (DEXA or clinical-grade bioimpedance): $75–$250 per scan; quarterly is standard.
- ·Nutrition therapy with a registered dietitian: $125–$300 per visit; some plans cover medical nutrition therapy for obesity or diabetes.
- ·Follow-up visits during titration (monthly for the first 4–6 months): $150–$400 each cash, or a standard copay with insurance.
- ·Bundled concierge GLP-1 programs in major markets typically run $400–$900 per month on top of the medication, including unlimited messaging, structured nutrition and training support, and quarterly labs and DEXA.
These costs separate medical weight loss from a $200/month compounded vial. A physician-led Ozempic program is a treatment for a chronic disease — priced and structured accordingly.
Frequently asked
Common questions
Is Ozempic covered for weight loss?
Not typically. Ozempic is FDA-approved for type 2 diabetes, and most commercial plans deny coverage when the diagnosis is obesity. For weight-loss-indicated coverage, Wegovy (semaglutide 2.4 mg) or Zepbound (tirzepatide) is usually required; coverage depends on the plan's obesity-drug formulary.
Why did my Ozempic price change?
Prices change because formularies update annually, prior authorizations expire and need renewal, savings card rules change, NovoCare Pharmacy adjusts its self-pay tiers, and pharmacies negotiate different acquisition costs. Re-check with your pharmacy each refill and reconfirm savings card eligibility once a year.
Is compounded semaglutide safe?
Compounded semaglutide is not FDA-approved. The FDA has documented dosing errors, adverse events, and salt-form substitutions (semaglutide sodium, semaglutide acetate) that are not the same active ingredient as Ozempic. With semaglutide off the FDA shortage list, routine compounding is generally not permitted, and physicians advise against it.
How much is Ozempic through NovoCare Pharmacy in 2026?
$199/month as an introductory rate on the first two fills of the 0.25 mg or 0.5 mg dose (offer runs through Dec 31, 2026).[4] After the introductory fills: $349/month for 0.25, 0.5, and 1 mg pens, and $499/month for 2 mg.
Does Medicare cover Ozempic?
Medicare Part D covers Ozempic for type 2 diabetes when formulary criteria are met. In 2026, Medicare Part D out-of-pocket spending is capped at $2,100,[6] which can substantially reduce annual cost. Medicare does not cover Ozempic when prescribed solely for weight loss.
When will a generic version lower the price?
Ozempic remains under patent in the U.S. Separately, Novo Nordisk plans to lower Ozempic's list price to $675/month on Jan 1, 2027.[3]
References
Sources
- 1.Ozempic (semaglutide) injection Prescribing Information (rev. 10/2025) — FDA / accessdata.fda.gov, 2025.
- 2.Ozempic Pen Frequently Asked Questions — Novo Nordisk, accessed Sep 2026.
- 3.Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus — Novo Nordisk (PR Newswire), Feb 24, 2026.
- 4.Get Your GLP-1 Medications Delivered with NovoCare Pharmacy — Novo Nordisk (NovoCare), accessed Sep 2026.
- 5.Start saving on Ozempic (Savings Offer) — Novo Nordisk (NovoCare), accessed Sep 2026.
- 6.2026 Medicare Advantage and Part D Rate Announcement — CMS, 2025.
- 7.Weight loss drugs (Medicare GLP-1 Bridge) — Medicare.gov, accessed Sep 2026.
- 8.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — FDA, updated Sep 1, 2026.
Related